GILD - FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer Competes With Gilead's Drug | Benzinga
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).
Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.